John A. Flygare
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cell death mechanisms and regulation, Monoclonal and Polyclonal Antibodies Research, Cancer Treatment and Pharmacology, Ubiquitin and proteasome pathways
Most-Cited Works
- → IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis(2007)1,198 cited
- → Novel antibody–antibiotic conjugate eliminates intracellular S. aureus(2015)820 cited
- → P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro(1997)540 cited
- → Structure-guided design of a selective BCL-XL inhibitor(2013)370 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)(2012)247 cited
- → Antibody‐Drug Conjugates for the Treatment of Cancer